MIFH
ALLO icon

Migdal Insurance & Financial Holdings’s Allogene Therapeutics ALLO Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,995
Closed -$741K – 584
2021
Q1 		$741K Buy
+20,995
New +$708K 0.01% 273

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Migdal Insurance & Financial Holdings's ALLO Position: Q2 2021 in Review

Migdal Insurance & Financial Holdings sold out of Allogene Therapeutics (ALLO) in Q2 2021, closing a stake of 20,995 shares — an estimated $741K sold.

Migdal Insurance & Financial Holdings first reported a position in ALLO in Q1 2021 and held it in 1 quarter. The position peaked at $741K in Q1 2021. 182 funds tracked by Wall St. Rank hold ALLO as of Q2 2021.

  • Migdal Insurance & Financial Holdings reported no remaining Allogene Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 20,995 Allogene Therapeutics shares in Q2 2021, an estimated $741K.
  • Migdal Insurance & Financial Holdings first reported a position in Allogene Therapeutics in Q1 2021 and held it in 1 quarter.
  • Migdal Insurance & Financial Holdings's Allogene Therapeutics position peaked at $741K in Q1 2021.
  • 182 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2021.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2021, filed 4 Aug 2021.